Difficulty: Medium
Average Score: 82%
Practice
A patient who will begin combination estrogen/progestin therapy (EPT) for menopause asks the nurse why she cannot take an estrogen-only preparation. The patient has not had a hysterectomy, has a slightly increased risk of cardiovascular disease, and has mild osteopenia. The nurse will tell her that the progestin is necessary to:
Correct answer
A
Rationale
The correct answer is A) decrease her risk of endometrial cancer. When a woman with an intact uterus takes estrogen therapy alone, it can lead to unopposed estrogen stimulation of the endometrium, increasing the risk of endometrial hyperplasia and cancer. Progestin is added to estrogen therapy to counteract this effect by inducing endometrial shedding, reducing the risk of endometrial cancer.
Option B) increase bone resorption to prevent fractures is incorrect because estrogen, not progestin, is known to have a positive effect on bone density by decreasing bone resorption and maintaining bone mass.
Option C) lower her risk of myocardial infarction (MI) is incorrect as there is conflicting evidence regarding the effects of hormone therapy on cardiovascular outcomes. Progestin is not specifically indicated for lowering the risk of MI.
Option D) prevent deep vein thrombosis (DVT) is incorrect because estrogen, not progestin, is associated with an increased risk of blood clots, including DVT. Progestin does not play a significant role in preventing DVT in this context.
In an educational context, understanding the rationale behind the addition of progestin to estrogen therapy is crucial for healthcare providers to appropriately counsel patients on the risks and benefits of hormone replacement therapy. This knowledge helps in individualizing treatment plans and promoting informed decision-making regarding menopausal symptom management and long-term health outcomes.
Option B) increase bone resorption to prevent fractures is incorrect because estrogen, not progestin, is known to have a positive effect on bone density by decreasing bone resorption and maintaining bone mass.
Option C) lower her risk of myocardial infarction (MI) is incorrect as there is conflicting evidence regarding the effects of hormone therapy on cardiovascular outcomes. Progestin is not specifically indicated for lowering the risk of MI.
Option D) prevent deep vein thrombosis (DVT) is incorrect because estrogen, not progestin, is associated with an increased risk of blood clots, including DVT. Progestin does not play a significant role in preventing DVT in this context.
In an educational context, understanding the rationale behind the addition of progestin to estrogen therapy is crucial for healthcare providers to appropriately counsel patients on the risks and benefits of hormone replacement therapy. This knowledge helps in individualizing treatment plans and promoting informed decision-making regarding menopausal symptom management and long-term health outcomes.